EcoDrugPlus

Janus Kinase 2

Ensembl ID : ENSRROG00000029878
Gene Symbol: JAK2
4 Cross references
265 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Janus Kinase 3

Ensembl ID : ENSRROG00000018975
Gene Symbol: JAK3
4 Cross references
103 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Kit Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSRROG00000040734
Gene Symbol: KIT
4 Cross references
265 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Lck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSRROG00000030948
Gene Symbol: LCK
4 Cross references
120 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Lyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSRROG00000026498
Gene Symbol: LYN
4 Cross references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Malt1 Paracaspase

Ensembl ID : ENSRROG00000038022
Gene Symbol: MALT1
2 Cross references
195 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mapk Activated Protein Kinase 2

Ensembl ID : ENSRROG00000038385
Gene Symbol: MAPKAPK2
1 Cross references
233 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mapk Activated Protein Kinase 5

Ensembl ID : ENSRROG00000030174
Gene Symbol: MAPKAPK5
4 Cross references
179 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mapk Interacting Serine/threonine Kinase 1

Ensembl ID : ENSRROG00000039899
Gene Symbol: MKNK1
4 Cross references
166 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mapk Interacting Serine/threonine Kinase 2

Ensembl ID : ENSRROG00000030837
Gene Symbol: MKNK2
4 Cross references
220 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mcl1 Apoptosis Regulator, Bcl2 Family Member

Ensembl ID : ENSRROG00000033266
Gene Symbol: MCL1
4 Cross references
236 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mdm2 Proto-Oncogene

Ensembl ID : ENSRROG00000045589
Gene Symbol: MDM2
2 Cross references
257 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).